



**Living Cell Technologies Ltd**

**COMPANY ANNOUNCEMENT**

**Living Cell Technologies Gains Additional Benefit From DIABECCELL®  
With Modified Diabetes Clinical Trial Protocol**

**April 6, 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)** reports insulin independence in a patient with insulin dependent type 1 diabetes who received DIABECCELL®, its encapsulated insulin-producing porcine cells, as part of an on-going Phase I/IIa clinical trial. The patient is a 37 year old woman who was on daily insulin injections for 15 years and now maintains good blood glucose control without insulin injections. Live porcine cells in intact capsules have been biopsied from the site of implants in the abdomen and porcine insulin was detected in the patient's blood.

LCT Medical Director, Professor Bob Elliott said, "Patients who have received the initial doses of the implants have clearly shown benefit."

Professor Elliott explained, "Early in the study, one patient attained insulin independence for eight weeks following the lowest dose of 5,000 islet equivalents (IEQ per kg body weight). She was given another implant at the lowest dose six months after the first. Subsequently, she required half the daily pre-implant insulin dose to maintain satisfactory blood glucose levels for the following year. A third implant of 8,000 IEQ per kg was administered and she again did not need insulin injections to maintain normal blood glucose levels."

Dr Paul Tan, LCT Chief Executive Officer, said, "These encapsulated cells offer not only an alternative but a physiological replacement therapy to provide new hope and improved lifestyles for people with diabetes.

At this early stage of clinical trials, results show that insulin independence is potentially achievable at least in some patients and that repeat implants are safe. LCT has narrowed product quality release specifications and responses to higher doses at first implants in future patients will clarify when and if repeat doses are necessary."

DIABECCELL® is LCT's encapsulated porcine insulin-producing cell product designed for the treatment of type 1 diabetes without the use of immunosuppressive drugs.

A total of seven patients have received DIABECCELL® implants in the safety and dose finding study. Patients were administered low or medium dose implants (5,000 to 10,000 islet equivalents (IEQs) per kg body weight) and some have had a repeat implant at least six months after the first. There have been no remarkable adverse events attributed to repeat implants.

Interim results from the trial conducted in Moscow has shown good blood glucose control as reflected by a reduction in glycated hemoglobin (% HbA1c) levels following the implants with reduction in daily insulin doses of varying magnitude for the implant doses administered to date.

-Ends-



**For further information:**

Dr. Paul Tan  
Chief Executive Officer  
Mob: 0402 716 984 (AUS)  
Mob: 021 608 784 (NZ)  
Tel: +64 9 270 794

Mr John Cowan  
Finance & Administration Manager  
Tel: +64 9 276 2690  
[jcowan@lctglobal.com](mailto:jcowan@lctglobal.com)

Prof. Bob Elliott  
Medical Director  
Mob: +64 27 292 4177  
Tel: +64 9 276 2690  
[relliott@lctglobal.com](mailto:relliott@lctglobal.com)

Rebecca Wilson  
Investor and Media Relations (ANZ)  
Mob: +61 417 382 391  
Tel: +61 3 9866 4722  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

**About Living Cell Technologies:** [www.lctglobal.com](http://www.lctglobal.com)

*Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For Parkinson's disease, Huntington's disease and other neurological disorders, the company is developing microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

**LCT Disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of December 2008 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.